Back to Report Store Home

ADHD therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations

  • Published: Jul-2014
  • Report Code: GBIHC337MR
  • Report Format: pdf

Description

Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.

Current treatment regimens, primarily in the form of psychostimulants, aim to reduce or prevent symptoms of hyperactivity, inattention, and impulsivity in order to improve quality of life. There is a significant need for new therapies in ADHD, but development is limited by the current clinical understanding of the disease. A total of 68 therapies are in active development in the ADHD pipeline and while many share mechanisms of action with marketed therapies, many have different dosing strategies in order to improve treatment compliance across the population.

Scope

  • Marketed therapies treat ADHD symptoms but are not curative; fundamental causes of the disease remain unknown.

  • When are stimulants and non-stimulants used in the ADHD treatment algorithm?

  • How do dominant marketed therapies compare clinically and commercially?

  • A relatively small pipeline focuses on established mechanisms of action, as a limited understanding of disease pathophysiology restricts innovative development.

  • How are pipeline therapies distributed by stage and mechanism of action?

  • What is the clinical trial attrition rate for monoaminergic agonists?

  • How long do ADHD trials last compared to CNS and industry averages?

  • Eight late-stage therapies are anticipated to reach the market in the forecast period, with differing clinical and commercial potential.

  • How have these therapies performed in clinical trials?

  • What are the competitive advantages of these therapies over marketed counterparts?

  • What is the sales forecast for Edivoxetine following its market launch?

  • The ADHD market is predicted to rise from $11.5 billion in 2013 to $13.3 billion in 2020 at a CAGR of 2.2% across the major markets.

  • Which market will show the greatest growth over the forecast period?

  • What makes the US the largest ADHD market?

  • How will generic erosion of prominent marketed therapies impact market value?

  • There have been 13 licensing deals and eight co-development deals pertaining to ADHD products since 2006.

  • Which territories show the greatest deal activity?

  • How are ADHD deals valued?

  • What were the conditions of the key licensing or co-development deals to take place in ADHD?

Reasons To Buy

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment algorithm currently used in ADHD.

  • Assess the safety and efficacy of current treatment options with extensive product profiles of prominent marketed therapies and a heatmap directly comparing safety and efficacy data.

  • Analyze the ADHD pipeline and stratify by stage of development, molecule type, and mechanism of action; promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

  • Predict growth in eight major markets using in-depth market forecasting between 2013 and 2020 to gain an understanding of how epidemiology trends, new drug entry, and patent expirations will influence market value.

  • Identify commercial opportunities in the ADHD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5817
Or click here to contact us
Secure Payments
Cards